|
Volumn 62, Issue 10, 2013, Pages
|
Comment on: Butler et al. marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
|
Author keywords
[No Author keywords available]
|
Indexed keywords
GLUCAGON;
GLUTAMATE DECARBOXYLASE ANTIBODY;
INCRETIN;
INSULIN ANTIBODY;
CONTROL GROUP;
DIABETES MELLITUS;
HUMAN;
LETTER;
NEUROENDOCRINE TUMOR;
PANCREAS;
PANCREAS ADENOMA;
PANCREAS ISLET;
PRIORITY JOURNAL;
STUDY DESIGN;
DRUG EFFECT;
FEMALE;
MALE;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PANCREAS ISLET BETA CELL;
DIABETES MELLITUS, TYPE 2;
DRUG EFFECTS;
DIABETES MELLITUS, TYPE 2;
FEMALE;
HUMANS;
INCRETINS;
INSULIN-SECRETING CELLS;
MALE;
PANCREAS;
|
EID: 84891525097
PISSN: 00121797
EISSN: 1939327X
Source Type: Journal
DOI: 10.2337/db13-0525 Document Type: Letter |
Times cited : (9)
|
References (6)
|